HAVCR2 and melanoma: A recent study also shows that TIM-3 blockade enhanced the antitumor effects of vaccine-induced response against established B16 murine melanomas via NK cell-dependent mechanisms [36], and this discrepancy may be possibly due to the different treatments and tumor microenvironments where TIM-3 may modulate distinct immune cells and the related signaling pathways that exist [36].